A CENSUS OF HUMAN CANCER GENES

By P. Futreal, L. Coin, Mhairi Marshall, Thomas A. Down, Tim J. P. Hubbard, R. Wooster, N. Rahman, Michael R. Stratton. Nature Reviews. Cancer, 2004

3,194 citations recorded by the source corpus.

A central aim of cancer research has been to identify the mutated genes that are causally implicated in oncogenesis ('cancer genes'). After two decades of searching, how many have been identified and how do they compare to the complete gene set that has been revealed by the human genome sequence? We have conducted a 'census' of cancer genes that indicates that mutations in more than 1% of genes contribute to human cancer. The census illustrates striking features in the types of sequence alteration, cancer classes in which oncogenic mutations have been identified and protein domains that are encoded by cancer genes.

Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/4871374a6fec685edcb6a5d7947554237f598210

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

In Pathology and Forensic Medicine

Citations in the corpus

Pattern discovery and cancer gene identification in integrated cancer genomic data (2013, background): “The full lists of known (27) and candidate cancer genes discovered by our method that characterize each cluster can be found in Dataset S2.”
The landscape of genomic alterations across childhood cancers (2018, neutral): “Furthermore, genes mutated in 2% of the cohort were included only if they had a secondary signal from either functional impact or from localized clustering bias (Intogen modules OncodriveFM and OncodriveClust v. 3.0 beta) or from being among known cancer genes 29,93 .”
OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes (2013, background): “Of note, this suggests that OncodriveCLUST could identify novel driver candidates (i.e. not included in the CGC) that are nevertheless overlooked by other methods and emphasizes the benefit of using a combination of methods to elucidate driver genes that balances the strengths and weaknesses of each”
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations (2017, background): “These were initially identified through experimentation, giving rise over the past 40 years to a stable census of human cancer genes [2].”
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing (2008, background): “128" language="eng" relation="no"> Somatic genetic changes involved in cancer causation include point mutations, genomic rearrangements and changes in copy numbe”
Integrative clinical genomics of advanced prostate cancer (2015, neutral): “1 or greater and a set of biologically relevant cancer genes (n = 550 genes) (Futreal et al., 2004).”
Selecting causal genes from genome-wide association studies via functionally-coherent subnetworks (2014, background): “The high gene rankings within the more complete SCGC set suggest that many of the cancer-linked genes at these 34 loci previously known only through somatic mutations may also harbor germline predisposition alleles.”
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (2018, positive): “REAGENT or RESOURCE SOURCE IDENTIFIER Critical Commercial Assays QIAamp Fast DNA Tissue Kit QIAGEN 51404 QIAamp DNA Blood Mini Kit QIAGEN 51104 Quant-iTTM PicoGreen dsDNA Reagent ThermoFisher P11496 Illumina DNA Sample Preparation HT Kit Illumina FC-121-2003 Agencourt AMPure XP Beads Beckman Coulter”